Trusted Market and Commodities-Trade Intelligence
On 27 Oct., 2015, Meihua Biotechnology Group Co., Ltd. (Meihua Bio) announced that to further integrate its company resources, reduce management levels, improve asset operation efficiency, save management expenses and lower operation management costs, it had decided to cancel one of its wholly-owned subsidiaries, namely Langfang Meihua Biotechnology Co., Ltd. (Langfang Meihua).
On 12 Aug., 2015, Meihua Biotechnology Group Co., Ltd. (Meihua Bio) published its H1 2015 report, according to which the company revenue increased by 33.6% year on year attributed to the growth in both sales volume and prices of its products.
On 9 July, 2015, Meihua Biotechnology Group Co., Ltd. (Meihua Bio) published its H1 2015 performance pre-announcement, according to which the company realized a net profit of USD21.7 million during the period, soaring by around 150% year on year.
On 21 May, 2015, Meihua Biotechnology Group Co., Ltd. (Meihua Bio) published a notice about the final decision from the United States International Trade Commission, Department of Commerce (ITC, DOC) on 18 May, 2015. In detail, it was decided that the three subsidiaries of Meihua Bio, Meihua Group International Trade (Hong Kong) Co., Ltd., Langfang Biotechnology Co., Ltd. and Xinjiang Meihua Amino Acids Co., Ltd., hadn’t sold products under normal prices in the US and there was no dumping of xanthan gum. Therefore, no anti-dumping tax should be levied on its xanthan gum exported to the US.
On 18 March, 2015, Meihua Biotechnology Group Co., Ltd. (Meihua Bio) published its 2014 annual report. Accordingly, the company’s revenue in 2014 increased by 26.8% year on year while its net profit went up by 23.9% year on year.
According to the Q3 report of Meihua Biotechnology Group Co., Ltd. (Meihua Bio), the company’s revenue in the first three quarters of 2014 reached USD1,182,741,262, up by 24.28% year on year. Meihua Bio is one of the main MSG players in the domestic market.
On 15 Nov., 2014, a domestic MSG giant, Meihua Biotechnology Group Co., Ltd. (Meihua Bio), announced to purchase 100% shares of Ningxia EPPEN Biotech Co., Ltd. (Ningxia EPPEN), with the price of USD621.2 million. After the completion of the transaction, the two enterprises’ market share in the domestic MSG and amino acid market will be improved further, making the industry embrace a new era.